GLOBAL MORQUIO SYNDROME (MPS-IV) DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global Morquio Syndrome (MPS-IV) Drug Market, By Product Type (Solid Dosage Form, Liquid Dosage Form), By Treatment (Enzyme Replacement Therapy, Hematopoietic Stem Cell Therapy, Gene Therapy, Others), By Disease Type (Morquio A, Morquio B), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : Jan 2024
Code : CMI6563
Pages :180
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Recent Developments

In March 2021, JCR Pharmaceuticals Co., Ltd., a pharmaceutical company, announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved IZCARGO (pabinafusp alfa 10 mL, intravenous drip infusion) for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome). IZCARGO is a recombinant iduronate-2-sulfatase enzyme replacement therapy (ERT) that relies on J-Brain Cargo, a proprietary technology developed by JCR, to deliver therapeutics across the blood-brain barrier (BBB).